A single-blinded, randomized, parallel intervention to evaluate genetics and omics-based personalized nutrition in general population via an e-commerce tool: The PREVENTOMICS e-commerce study.

dietary patterns genome-wide association studies health status healthy diets lifestyle intervention physiologic characterization precision nutrition targeted nutrition

Journal

The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 26 09 2023
revised: 04 03 2024
accepted: 02 04 2024
medline: 4 7 2024
pubmed: 4 7 2024
entrez: 3 7 2024
Statut: ppublish

Résumé

Personalized nutrition (PN) has been proposed as a strategy to increase the effectiveness of dietary recommendations and ultimately improve health status. We aimed to assess whether including omics-based PN in an e-commerce tool improves dietary behavior and metabolic profile in general population. A 21-wk parallel, single-blinded, randomized intervention involved 193 adults assigned to a control group following Mediterranean diet recommendations (n = 57, completers = 36), PN (n = 70, completers = 45), or personalized plan (PP, n = 68, completers = 53) integrating a behavioral change program with PN recommendations. The intervention used metabolomics, proteomics, and genetic data to assist participants in creating personalized shopping lists in a simulated e-commerce retailer portal. The primary outcome was the Mediterranean diet adherence screener (MEDAS) score; secondary outcomes included biometric and metabolic markers and dietary habits. Volunteers were categorized with a scoring system based on biomarkers of lipid, carbohydrate metabolism, inflammation, oxidative stress, and microbiota, and dietary recommendations delivered accordingly in the PN and PP groups. The intervention significantly increased MEDAS scores in all volunteers (control-3 points; 95% confidence interval [CI]: 2.2, 3.8; PN-2.7 points; 95% CI: 2.0, 3.3; and PP-2.8 points; 95% CI: 2.1, 3.4; q < 0.001). No significant differences were observed in dietary habits or health parameters between PN and control groups after adjustment for multiple comparisons. Nevertheless, personalized recommendations significantly (false discovery rate < 0.05) and selectively enhanced the scores calculated with biomarkers of carbohydrate metabolism (β: -0.37; 95% CI: -0.56, -0.18), oxidative stress (β: -0.37; 95% CI: -0.60, -0.15), microbiota (β: -0.38; 95% CI: -0.63, -0.15), and inflammation (β: -0.78; 95% CI: -1.24, -0.31) compared with control diet. Integration of personalized strategies within an e-commerce-like tool did not enhance adherence to Mediterranean diet or improved health markers compared with general recommendations. The metabotyping approach showed promising results and more research is guaranteed to further promote its application in PN. This trial was registered at clinicaltrials.gov as NCT04641559 (https://clinicaltrials.gov/study/NCT04641559?cond=NCT04641559&rank=1).

Sections du résumé

BACKGROUND BACKGROUND
Personalized nutrition (PN) has been proposed as a strategy to increase the effectiveness of dietary recommendations and ultimately improve health status.
OBJECTIVES OBJECTIVE
We aimed to assess whether including omics-based PN in an e-commerce tool improves dietary behavior and metabolic profile in general population.
METHODS METHODS
A 21-wk parallel, single-blinded, randomized intervention involved 193 adults assigned to a control group following Mediterranean diet recommendations (n = 57, completers = 36), PN (n = 70, completers = 45), or personalized plan (PP, n = 68, completers = 53) integrating a behavioral change program with PN recommendations. The intervention used metabolomics, proteomics, and genetic data to assist participants in creating personalized shopping lists in a simulated e-commerce retailer portal. The primary outcome was the Mediterranean diet adherence screener (MEDAS) score; secondary outcomes included biometric and metabolic markers and dietary habits.
RESULTS RESULTS
Volunteers were categorized with a scoring system based on biomarkers of lipid, carbohydrate metabolism, inflammation, oxidative stress, and microbiota, and dietary recommendations delivered accordingly in the PN and PP groups. The intervention significantly increased MEDAS scores in all volunteers (control-3 points; 95% confidence interval [CI]: 2.2, 3.8; PN-2.7 points; 95% CI: 2.0, 3.3; and PP-2.8 points; 95% CI: 2.1, 3.4; q < 0.001). No significant differences were observed in dietary habits or health parameters between PN and control groups after adjustment for multiple comparisons. Nevertheless, personalized recommendations significantly (false discovery rate < 0.05) and selectively enhanced the scores calculated with biomarkers of carbohydrate metabolism (β: -0.37; 95% CI: -0.56, -0.18), oxidative stress (β: -0.37; 95% CI: -0.60, -0.15), microbiota (β: -0.38; 95% CI: -0.63, -0.15), and inflammation (β: -0.78; 95% CI: -1.24, -0.31) compared with control diet.
CONCLUSIONS CONCLUSIONS
Integration of personalized strategies within an e-commerce-like tool did not enhance adherence to Mediterranean diet or improved health markers compared with general recommendations. The metabotyping approach showed promising results and more research is guaranteed to further promote its application in PN. This trial was registered at clinicaltrials.gov as NCT04641559 (https://clinicaltrials.gov/study/NCT04641559?cond=NCT04641559&rank=1).

Identifiants

pubmed: 38960570
pii: S0002-9165(24)00394-0
doi: 10.1016/j.ajcnut.2024.04.004
pii:
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT04641559']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-144

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Lorena Calderón-Pérez (L)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Xavier Escoté (X)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Judit Companys (J)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Juan María Alcaide-Hidalgo (JM)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Mireia Bosch (M)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Montserrat Rabassa (M)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain; Departament de Nutrició, Ciències de l'Alimentació i Gastronomia, Nutrition and Food Safety Research Institute (INSA), Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), Barcelona, Spain.

Anna Crescenti (A)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Rosa M Valls (RM)

Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain.

Anna Pedret (A)

Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain.

Rosa Solà (R)

Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain; Internal Medicine Service, Hospital Universitari Sant Joan de Reus, Reus, Spain.

Roger Mariné (R)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Katherine Gil-Cardoso (K)

Eurecat, Centre Tecnològic de Catalunya, Nutrition and Health Unit, Reus, Spain.

Miguel A Rodríguez (MA)

Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Spain.

Héctor Palacios (H)

Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Spain.

Antoni Del Pino (A)

Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Spain.

María Guirro (M)

Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Spain.

Núria Canela (N)

Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences (COS), Joint Unit Universitat Rovira i Virgili-EURECAT, Unique Scientific and Technical Infrastructures (ICTS), Reus, Spain.

David Suñol (D)

Eurecat, Centre Tecnològic de Catalunya, Digital Health, Barcelona, Spain.

Mar Galofré (M)

Eurecat, Centre Tecnològic de Catalunya, Digital Health, Barcelona, Spain.

Sebastià Galmés (S)

Laboratory of Molecular Biology, Nutrition and Biotechnology (Group of Nutrigenomics, Biomarkers and Risk Evaluation - NuBE), University of the Balearic Islands, Palma, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Centro de investigación Biomédica en red de Fisiopatología de la obesidad y nutrición, Instituto de Salud Carlos III, Madrid, Spain; Alimentómica S.L. Camí de na Pontons, Campanet, Spain.

Andreu Palou-March (A)

Laboratory of Molecular Biology, Nutrition and Biotechnology (Group of Nutrigenomics, Biomarkers and Risk Evaluation - NuBE), University of the Balearic Islands, Palma, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Centro de investigación Biomédica en red de Fisiopatología de la obesidad y nutrición, Instituto de Salud Carlos III, Madrid, Spain; Alimentómica S.L. Camí de na Pontons, Campanet, Spain.

Francisca Serra (F)

Laboratory of Molecular Biology, Nutrition and Biotechnology (Group of Nutrigenomics, Biomarkers and Risk Evaluation - NuBE), University of the Balearic Islands, Palma, Spain; Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain; Centro de investigación Biomédica en red de Fisiopatología de la obesidad y nutrición, Instituto de Salud Carlos III, Madrid, Spain; Alimentómica S.L. Camí de na Pontons, Campanet, Spain.

Antoni Caimari (A)

Eurecat, Centre Tecnològic de Catalunya, Biotechnology Area, Reus, Spain.

Biotza Gutiérrez (B)

Eurecat, Centre Tecnològic de Catalunya, Biotechnology Area, Reus, Spain.

Josep M Del Bas (JM)

Eurecat, Centre Tecnològic de Catalunya, Biotechnology Area, Reus, Spain. Electronic address: Josep.delbas@eurecat.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH